BRPI0816268A2 - Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólida - Google Patents

Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólida

Info

Publication number
BRPI0816268A2
BRPI0816268A2 BRPI0816268A BRPI0816268A BRPI0816268A2 BR PI0816268 A2 BRPI0816268 A2 BR PI0816268A2 BR PI0816268 A BRPI0816268 A BR PI0816268A BR PI0816268 A BRPI0816268 A BR PI0816268A BR PI0816268 A2 BRPI0816268 A2 BR PI0816268A2
Authority
BR
Brazil
Prior art keywords
dosage form
controlled release
oral dosage
solid oral
release solid
Prior art date
Application number
BRPI0816268A
Other languages
English (en)
Inventor
Pillai Radhakrishnan
Sarpotdar Pramod
W Osborne David
J Dow Gordon
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Publication of BRPI0816268A2 publication Critical patent/BRPI0816268A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMA DE DOSAGEM ORAL SÓLIDA DE LIBERAÇÃO CONTROLADA, MÉTODO PARA FABRICAR UMA FORMA DE DOSAGEM SÓLIDA DE LIBERAÇÃO CONTROLADA E MÉTODO PARA AUMENTAR A BIODISPONIBILIDADE DA AZITROMICINA EM UMA FORMA DE DOSAGEM ORAL SÓLIDA. Uma forma de dosagem sólida para administração oral compreende azitromicina em uma quantidade que é inferior aquela que causa efeitos colaterais gastrointestinais cuja forma de dosagem é uma forma de dosagem de liberação controlada.
BRPI0816268A 2007-09-05 2008-07-30 Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólida BRPI0816268A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96750407P 2007-09-05 2007-09-05
US12/002,417 US8124123B2 (en) 2007-09-05 2007-12-17 Controlled release azithromycin solid dosages forms
PCT/US2008/009169 WO2009032037A1 (en) 2007-09-05 2008-07-30 Controlled release azithromycin solid dosages forms

Publications (1)

Publication Number Publication Date
BRPI0816268A2 true BRPI0816268A2 (pt) 2017-08-22

Family

ID=40407900

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816268A BRPI0816268A2 (pt) 2007-09-05 2008-07-30 Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólida

Country Status (12)

Country Link
US (2) US8124123B2 (pt)
EP (2) EP2197420A4 (pt)
JP (2) JP2010538062A (pt)
KR (2) KR20100063088A (pt)
CN (2) CN101861138A (pt)
AR (1) AR068368A1 (pt)
AU (2) AU2008295579A1 (pt)
BR (1) BRPI0816268A2 (pt)
CA (2) CA2697496A1 (pt)
RU (2) RU2010109358A (pt)
WO (2) WO2009032037A1 (pt)
ZA (2) ZA201001649B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
CN109875970B (zh) * 2019-01-08 2021-08-06 石家庄四药有限公司 阿奇霉素固体制剂及其制备方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
AU7888298A (en) * 1997-01-03 1998-07-31 Elan Corporation, Plc Sustained release cisapride minitablet formulation
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7994214B2 (en) * 2003-08-29 2011-08-09 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
JP2008524317A (ja) 2004-12-21 2008-07-10 ファイザー・プロダクツ・インク 腸溶コーティングされたアジスロマイシン多粒子
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
EP2074992B1 (en) * 2005-04-08 2015-05-20 Abbott Laboratories Oral pharmaceutical formulations comprising salts of fenofibric acid
AU2006336612A1 (en) * 2005-11-09 2007-08-02 Dow Pharmaceutical Sciences Azithromycin for treatment of granulomatous rosacea
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne

Also Published As

Publication number Publication date
AU2008295579A1 (en) 2009-03-12
ZA201001649B (en) 2010-11-24
RU2010109358A (ru) 2011-10-20
EP2197453A4 (en) 2010-10-20
ZA201001705B (en) 2010-12-29
EP2197420A1 (en) 2010-06-23
CA2697537A1 (en) 2009-03-12
WO2009032268A1 (en) 2009-03-12
CA2697496A1 (en) 2009-03-12
KR20100063088A (ko) 2010-06-10
US8124123B2 (en) 2012-02-28
RU2010109359A (ru) 2011-10-20
AU2008296903A1 (en) 2009-03-12
AR068368A1 (es) 2009-11-11
JP2010538062A (ja) 2010-12-09
CN101835475A (zh) 2010-09-15
US20120121702A1 (en) 2012-05-17
JP2010538066A (ja) 2010-12-09
EP2197453A1 (en) 2010-06-23
US20090060994A1 (en) 2009-03-05
EP2197420A4 (en) 2010-10-20
WO2009032037A1 (en) 2009-03-12
CN101861138A (zh) 2010-10-13
KR20100054842A (ko) 2010-05-25

Similar Documents

Publication Publication Date Title
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
DK2077729T3 (da) Orale probiotiske doseringsformer
BRPI0816268A2 (pt) Forma de dosagem oral sólida de liberação controlada, método para fabricar uma forma de dosagem sólida de liberação controlada e método para aumentar a biodisponibilidade da azitromicina em uma forma de dosagem oral sólida
BR112014014025A2 (pt) prótese luminal e dispostivo de implante gastrointestinal
GB0720297D0 (en) Web server administration
ZA200904436B (en) Modified release ibuprofen solid oral dosage form
BRPI0916689A2 (pt) composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI0814299A2 (pt) Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
PL2457563T3 (pl) Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego
BR112012000968A2 (pt) composto, composição e método para inibir uma fosfatidil inositol-3 cinase.
BRPI0907024A2 (pt) Técnicas para gerar uma composição visual para um evento de conferência de multimídia
ZA201005015B (en) Solid pharmaceutical dosage form
IL212008A0 (en) Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
CL2008000914A1 (es) Forma de dosificacion de liberacion modificada de tacrolimus.
FR2945947B1 (fr) Compositions pharmaceutiques flottantes a liberation controlee
IL202743A0 (en) Stabilized picoplatin dosage form
BRPI0719502A2 (pt) Película, artigo, pacote e método para formar uma película multicamada
BRPI0810727A2 (pt) Dispositivo para a aplicação oral de uma substância.
ZA201100615B (en) Appetising medicament for oral administration in solid form
BRPI0908114A2 (pt) tabuleta oral de liberação controlada
BRPI0719880A2 (pt) Forma de dosagem sólida farmacêutica para administração oral e método para preparar a mesma.
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
GB0710439D0 (en) Oral dosage form
BRPI0812964A2 (pt) Forma de dosagem farmacêutica oral sólida

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.